Cite
HARVARD Citation
Spigel, D. et al. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of clinical oncology. 40 (12), pp. 1301-1311. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Spigel, D. et al. (2022). Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of clinical oncology. 40 (12), pp. 1301-1311. [Online].